Don’t miss our poster presentation at ASCO 2025.
Colorectal cancer (CRC) is the third most common cancer worldwide and a leading cause of cancer mortality, with ~33% of patients developing metastases and a poor 5-year survival rate of ~15%.
While surgical resection offers a potential cure for a subset of metastatic CRC (mCRC) patients, tools to predict post-surgical outcomes remain inadequate. There is a critical need for non-invasive biomarkers that can guide treatment decisions and identify patients likely to benefit from curative surgery.
Join our Senior Scientist for Translational Research, Ceyda Coruh, on May 31 (9:00 AM – 12:00 PM) for a poster presentation on how 5-hydroxymethylcytosine (5hmC) of cell-free DNA (cfDNA) offers a novel, non-invasive approach for identification of colorectal cancer biology and assessment of treatment response in blood samples.
🤝 Reach out directly to Ceyda to schedule a meeting at the event.
Abstract Number: 3585
Cell-free DNA 5-hydroxymethylcytosine Profiling for the Assessment of Colorectal Cancer Biology and Treatment Response in Blood.
Date & Time: 05/31, 9:00 AM – 12:00 PM